Clinical Trials

Placebo-controlled Phase 1/2

Our first placebo-controlled Phase 1/2 clinical trial, conducted at Massachusetts General Hospital, found that a single topical dose of our SX770 formulation tripled median time to next outbreak from 40 days in the placebo group to >124 days in the treatment group (p<0.01).

See: https://clinicaltrials.gov/ct2/show/NCT01971385

and https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817593/

Mechanism of Action Clinical Trial

Our second clinical trial studied the immune gene expression of persons infected with HSV-1 who had frequent cold sores (≥6 episodes per year) versus those with few episodes, and found many differences in immune gene expression between the groups, including significantly greater interferon gamma expression in persons with few or no outbreaks.

We then dosed the persons who had frequent outbreaks once on the arm with SQX770.  This caused their immune gene signature to be more like the persons with few or no outbreaks in every respect, including significantly greater interferon-gamma expression.

See: https://www.ncbi.nlm.nih.gov/pubmed/30756512

Phase 2 Clinical Trial

We have conducted a larger placebo-controlled clinical trial at Massachusetts General Hospital, Stanford University, and other sites in approximately 140 persons with 4 or more herpes labialis outbreaks per year.  We will announce the results shortly. 

See: https://clinicaltrials.gov/ct2/show/NCT02965781